DOV-216,303
(Redirected from
DOV-216303
)Legal status | |
---|---|
Legal status | |
Identifiers | |
| |
JSmol) | |
| |
| |
(what is this?) (verify) |
DOV 216,303 is an experimental antidepressant drug originally developed by DOV Pharmaceutical and was licensed to Merck & Co. in 2004;[1] Merck and DOV terminated their relationship in December 2006.[2]: 12 [3]
It is a
racemic mixture of amitifadine (DOV-21,947) and its (–)-enantiomer, DOV-102,677. Its IC50 values for SERT, NET, and DAT are Ki 14 nM, 20 nM, and 78 nM, respectively.[4]
As of March 2008, DOV had no intention to further develop DOV-216,303 because the patent on the compound had expired.[2]: 6
In a
contusion.[5]
See also
References
- ^ McCoy M (August 12, 2004). "Merck and DOV Pharmaceutical In Drug Pact". Chemical & Engineering News.
- ^ a b "10-K For the fiscal year ended December 31, 2007". Dov Pharmaceutical via SEC Edgar. March 31, 2008.
DOV 216,303 was originally in development for depression; however as the patented composition of matter claim has expired, there are no ongoing clinical trials of DOV 216,303 and none are planned.
- ^ "DOV 216303". Adis Insight. Springer Nature Switzerland AG. Retrieved 26 February 2017.
- ^ PMID 16958986.
- S2CID 5007186.